Skip to main content

Mesoblast Limited (MESO)

NASDAQ: MESO · IEX Real-Time Price · USD
6.19 -0.19 (-2.98%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap801.48M
Revenue (ttm)9.75M
Net Income (ttm)-96.91M
Shares Out129.48M
EPS (ttm)-0.82
PE Ration/a
Forward PE454.55
Dividendn/a
Ex-Dividend Daten/a
Volume84,895
Open6.65
Previous Close6.38
Day's Range6.01 - 6.30
52-Week Range5.52 - 17.41
Beta2.46
Analystsn/a
Price Targetn/a
Earnings DateNov 18, 2021

About MESO

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L fo...

IndustryBiotechnology
Founded2004
CEOSilviu Itescu
Employees83
Stock ExchangeNASDAQ
Ticker SymbolMESO
Full Company Profile

Financial Performance

In 2021, Mesoblast's revenue was $7.46 million, a decrease of -76.81% compared to the previous year's $32.16 million. Losses were -$98.81 million, 26.8% more than in 2020.

Financial Statements

News

Operational Highlights and Financial Results for the Period Ended September 30, 2021

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and ...

4 days ago - GlobeNewsWire

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational...

4 days ago - GlobeNewsWire

Mesoblast Announces Debt Refinancing And Expansion With Oaktree Capital

Mesoblast Limited (NASDAQ: MESO) refinanced its existing senior debt facility with a new $90 million five-year facility provided by Oaktree Capital Management LP. Mesoblast drew the first tranche of $60...

5 days ago - Benzinga

Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully r...

6 days ago - GlobeNewsWire

Mesoblast's Remestemcel Shows Promising Action In Patients With Heart Failure

Mesoblast Limited (NASDAQ: MESO) presented new results from the landmark Phase 3 study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Data w...

1 week ago - Benzinga

Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L...

Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation

1 week ago - GlobeNewsWire

Appendix 4C Quarterly Activity Report

Financial and Operational Highlights for Quarter Ended September 30, 2021 Financial and Operational Highlights for Quarter Ended September 30, 2021

4 weeks ago - GlobeNewsWire

Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American He...

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the rand...

1 month ago - GlobeNewsWire

Why Mesoblast Stock Is Plunging After Q4 Earnings Report?

Mesoblast Limited (NASDAQ: MESO) shares dived on Tuesday as the FDA raised more questions around its flagship drug candidate, and its annual loss widened.  What Happened: In the June quarter, Mesoblast ...

2 months ago - Benzinga

Operational Highlights and Financial Results for the Year Ended June 30, 2021

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and ...

2 months ago - GlobeNewsWire

Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial

Mesoblast Limited (NASDAQ: MESO) has announced the presentation of 90-day survival outcomes from the remestemcel-L trial in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory ...

4 months ago - Benzinga

Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & ...

NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from th...

4 months ago - GlobeNewsWire

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the...

4 months ago - GlobeNewsWire

Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain

Mesoblast Limited (NASDAQ: MESO) provided an update on the strategy for bringing rexlemestrocel-L to patients in the U.S. with chronic low back pain (CLBP) due to degenerative disc disease refractory to...

4 months ago - Benzinga

Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy f...

4 months ago - GlobeNewsWire

Operational Highlights and Financial Results for the Period Ended March 31, 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and ...

5 months ago - GlobeNewsWire

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss opera...

5 months ago - GlobeNewsWire

Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed jour...

6 months ago - GlobeNewsWire

Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?

Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down...

6 months ago - Zacks Investment Research

Why Mesoblast Limited Stock Is Jumping Today

The company announced positive results from a clinical trial.

6 months ago - The Motley Fool

Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Di...

Mesoblast Limited (NASDAQ: MESO) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS), ...

6 months ago - Benzinga

Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021 Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021

6 months ago - GlobeNewsWire

Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day...

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from t...

6 months ago - GlobeNewsWire

Mesoblast Corporate Update

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a co...

6 months ago - GlobeNewsWire

Mesoblast Operational Highlights and Upcoming Milestones

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Company...

7 months ago - GlobeNewsWire